Quantcast

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

May 5, 2014

LONDON, May 5, 2014 /PRNewswire/ — Reportbuyer.com has added a new market research report:

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.html

Report Details

Treating abnormal bleeding – this new report shows you trends, R&D outlooks, and sales forecasts

Treatments for bleeding – what’re their prospects? Visiongain’s new report gives you predictions for drugs controlling those blood clotting diseases. Stay ahead then. You discover financial results, technologies, R&D trends, opportunities, and forecasted revenues.

So you see what’s possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.

Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.

Forecasts and other information explaining lucrative possibilities for treatments

Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.

Futures of medicines stopping and preventing haemorrhaging – data to help your work

Our study concludes that, from 2014, patients, healthcare providers, and pharma companies will gain from that medical and technological progress. Hear what’s possible.

Find there how you can help your research, analyses, and decisions. Also save time. And discover how you could benefit your authority through better understanding the future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments – see what’s likely to happen

What’s that industry’s potential? What’re the secrets of its progress? Discover in our report overall world revenue to 2024 for pharmaceuticals controlling bleeding.

Also you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
– Haemophilia A
– Haemophilia B
– Thrombocytopenia
– Related diseases (other coagulation factor deficiencies, grouped).

How will those markets expand? Which classes of therapy will generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales. Also you assess products’ futures.

Predicting of existing and expected therapies’ revenues

Find sales outlooks for top brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these:
– Advate
– NovoSeven
– Kogenate
– BeneFIX
– FEIBA.

You also get revenue predictions for five expected agents, including these:
– Rixubis
– Eloctate
– Alprolix.

There you find drugs and years with highest predicted sales rises. Also you examine competitors. You see what’s happening, then, understanding challenges, competition, opportunities, and successes.

Our work also divides its overall prediction into geographical regions.

Healthcare in national markets – what outlooks for business?

In developed and developing countries, opportunities for providers of those products and technologies will occur from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
– United States (US)
– Japan
– Germany, France, UK, Italy, and Spain (EU5)
– Brazil, Russia, India, and China (BRIC nations).

There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.

Explore, too, how that haematological technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.

Events and forces for developing, producing, marketing, and selling blood-stemming drugs

The report shows you issues and events affecting that industry from 2014, including these:
– Advances in understanding haemostasis and coagulation aiding science and product development
– Needle-free drug delivery and other innovations
– Synthetic purification processes and other novel techniques for making biologics and biosimilars
– Long-acting clotting factor therapy and recombinant coagulation factors
– Use of prophylactic schedules (prophylaxis) increasing
– Regulators, pricing, and other challenges – approvals, costs, and concerns.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry and affects results.

Companies and overall 2017 market value – find outlook for success

What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.

So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.

In particular, then, you explore activities and prospects of these companies:
– Baxter
– Novo Nordisk
– Bayer
– Pfizer
– CSL Behring.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.

Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps

In particular, our new investigation gives you these advantages:
– Revenues there to 2024 at world level, for 4 submarkets, and 15 products – assess outlooks for production, marketing, and sales
– Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – examine developed and developing countries for potential revenues
– Prospects for established competitors, emerging companies, and new entrants – investigate portfolios, results, strategies, developmental activities, and successes.

Information found nowhere else, helping your searches, analyses, and decisions

Our new study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore commercial possibilities.

With that data you’re less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort with our study, aiding your decisions.

You discover original insights then. So act now in advance of your rivals, also benefiting your authority.
1. Executive Summary

1.1 What This Report Covers
1.2 Bleeding Disorders: World Pharma Industry and Market Overview 2013-2024
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Bleeding Disorders

2.1 Understanding Haemostasis and Coagulation
2.1.1 Vascular Spasm
2.1.2 Platelet Activation and Aggregation
2.1.3 Coagulation
2.2 An Introduction to the Bleeding Disorders and Their Treatment
2.2.1 Haemophilia A, B and C
2.2.2 Von Willebrand Disease
2.2.3 Thrombocytopenia

3. The World Pharmaceutical Market for Bleeding Disorders 2014-2024

3.1 The World Pharmaceutical Market for Bleeding Disorders in 2012
3.2 The Bleeding Disorders Pharmaceutical Market: An Overarching Revenue Forecast 2014-2024
3.3 The Pharmaceutical Market by Bleeding Disorder: Comparison of Revenue and Market Share, 2018 and 2024
3.4 The World Pharmaceutical Market for Bleeding Disorders by Therapeutic Subclass: Grouped Revenue Forecasts 2014-2024
3.5 Haemophilia A Accounted for Almost 70% of the Market in 2012
3.6 Haemophilia B Will See Increasing Prominence in the Bleeding Disorders Market
3.7 Thrombocytopenia
3.8 Other Coagulation Factor Deficiencies
3.9 Summary of the Research and Analyses

4. Leading Drugs of the Market for Treating Bleeding Disorders, 2014-2024

4.1 The Leading Drugs for the Treatment of Bleeding Disorders in 2012
4.2 Leading Bleeding Disorder Drugs: Comparison of Revenue and Market Share, 2018 and 2024
4.3 Leading Bleeding Disorder Drugs: A Grouped Revenue Forecast, 2014-2024
4.4 Advate Will Continue to Dominate the Market
4.5 NovoSeven: Patent Protection Has Expired, But Revenue Generation Remains Strong
4.6 Kogenate: Needle-Free Delivery Makes it an Attractive Option for Patients
4.7 BeneFIX Faces Competition in 2013 – How Will This Affect Revenue?
4.8 FEIBA: The Original Treatment for Disease with Inhibitors
4.9 ReFacto/ Xyntha: Produced Using an Entirely Synthetic Purification Process
4.10 Helixate: Marketing Agreement With Bayer Extends Until 2017
4.11 Nplate: The Leading Product for Thrombocytopenia in 2012
4.12 Alphanate: A Staple Treatment for Bleeding Disorders Since 1978
4.13 Promacta Competes With Nplate, But Which Will Prove Most Successful?
4.14 Promising Compounds in the Developmental Pipeline
4.14.1 Rixubis: The First Recombinant FIX Treatment Factor for Routine Prophylaxis in Haemophilia B
4.14.2 Eloctate: The First Long-Acting Clotting Factor Therapy for Haemophilia A?
4.14.3 Alprolix: The First Long-Acting Clotting Factor Treatment for Haemophilia B?
4.14.4 N8-GP: Novo Nordisk’s Long Acting Compound for the Treatment of Haemophilia A
4.14.5 N9-GP: Novo Nordisk’s Long-Acting Treatment for Haemophilia B

5. The Leading National Pharmaceutical Markets for Bleeding Disorders, 2014-2024

5.1 The Leading National Markets for Bleeding Disorders: The US Dominates in 2012
5.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 2024
5.3 Leading National Pharmaceutical Markets for Bleeding Disorders: Grouped Revenue Forecasts, 2014-2024
5.4 The US Will Continue to Dominate the Bleeding Disorders Market Throughout the Forecast Period
5.5 The EU5: What Prospects There?
5.5.1 Germany Will Remain the Largest of the EU5 Markets
5.5.2 France: Increasing Uptake of Prophylactic Therapy Will Drive Growth
5.5.3 Italy: The 3rd Largest Market of the EU5
5.5.4 The UK: Well Developed Infrastructure for the Treatment of Bleeding Disorders
5.5.5 Spain: Use of Recombinant Coagulation Factors is Relatively Low at Present
5.6 Japan: Use of Prophylactic Treatment is Lower Than That of the Western World
5.7 China: A Growing Domestic Bleeding Disorders Pharmaceutical Market
5.8 Brazil: Baxter Will Be the Exclusive Provider of Recombinant Therapy for the Next 10 Years
5.9 India: 90% of Patients Are Unable to Afford Treatment Costs
5.10 Russia: Treatment Levels Per Capita Are High

6. Bleeding Disorders: R&D Pipelines, 2013

6.1 The R&D Pipeline for Bleeding Disorders: An Overview
6.2 Four Candidates Are In Pre-Registration
6.2.1 Novo Nordisk’s NovoEight
6.2.2 Novo Nordisk’s NovoThirteen: Denied Approval by the FDA for the Second Time; Will It Be Third Time Lucky?
6.2.3 Biogen Idec’s Eloctate: The First Long-Acting Treatment for Haemophilia A?
6.2.4 Biogen Idec’s Alprolix: The First Long-Acting Treatment for Haemophilia B?
6.3 The Phase III Development Pipeline: Novo Nordisk Has a Strong Presence
6.3.1 Novo Nordisk’s N8-GP and N9-GP: Second in Class Treatments?
6.3.2 Baxter’s rFVIIa BI
6.3.3 Octapharma’s Human-cl rhFVIII
6.4 The Phase II/III Development Pipeline: An Abundance of Haemophilia A Treatments
6.4.1 Baxter’s BAX855: Another Long-Acting Haemophilia A Treatment
6.4.2 Baxter has Purchased OBI-1 from Inspiration Biopharmaceuticals
6.5 The Phase I/II Development Pipeline: Gene Therapy for Haemophilia B
6.6 The Phase I Development Pipeline: Offerings from Novo Nordisk and Pfizer
6.6.1 Novo Nordisk’s mAb2021
6.6.2 Pfizer’s PF-05280602

7. Leading Companies of the Bleeding Disorders Pharmaceutical Market

7.1 The Leading Companies of the Bleeding Disorders Pharmaceutical Market
7.2 Baxter Accounted for Over 30% of the Bleeding Disorders Market in 2012, But Will It Remain Market Leader?
7.3 Novo Nordisk: Demonstrating Commitment to Treating Bleeding Disorders
7.4 Bayer: A Limited Product Portfolio?
7.5 Pfizer: Declining Market Share During the Forecast Period?
7.6 CSL Behring Has the largest Portfolio of Bleeding Disorder Drugs
7.7 Grifols Will Have a Declining Market Share
7.8 Amgen: Single Stake in the Bleeding Disorders Market
7.9 Octapharma: Branching Into Recombinant Coagulation Factors
7.10 GSK: Bleeding Disorders Are Not a Main Therapeutic Focus
7.11 Biogen Idec: Market Entry Anticipated in 2014

8. Qualitative Analysis of the Bleeding Disorders Pharmaceutical Market, 2013-2024

8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013
8.1.1 Treatment of Bleeding is Essential
8.1.2 The Threat of Generic/Biosimilar Competition is Low
8.1.3 Advances in Technology Have Improved Treatment Options
8.1.4 A Small Patient Population Ultimately Restricts the Market
8.1.5 Emerging National Markets: Patients Often Having Little Access to Treatments
8.1.6 High Barriers to Market Entry
8.1.7 The Burden of Prophylactic Therapy
8.2 The Opportunities and Threats Facing the Market, 2014-2024
8.2.1 Low Switch Rate Among Patients Receiving Treatment for Bleeding Disorders: An Opportunity and a Threat
8.2.2 Demand for Treatment in the Emerging Markets is Increases, But Are Recombinant Therapies Too Expensive?
8.2.3 High Barriers to Market Entry Will Limit Competition, But Also Limit Development
8.3 Social, Technological, Economic and Political Forces Influencing the Bleeding Disorders Pharmaceutical Market, 2014-2024
8.3.1 Social Factors
8.3.2 Technological Factors
8.3.3 Economic Factors
8.3.4 Political Factors

9. Research Interview

9.1 Interview With Dr Kamran Kamyar, M.D., Medical Manager, AryoGen Biopharma
9.1.1 On the State of the Current Market
9.1.2 On AryoGen’s Presence in the Market
9.1.3 On Important Developments in the Industry

10. Conclusions from Our Study

10.1 The World Pharmaceutical Market for Bleeding Disorders, 2014-2024
10.2 Bleeding Disorders: Leading Products on the Market, 2014-2024
10.3 Leading National Markets for the Bleeding Disorder Pharmaceutical Industry, 2014-2024
10.4 Trends in that Industry and Market
10.4.1 Bleeding Disorders Are Serious Conditions Requiring Frequent Drug Treatment
10.4.2 The Demand for Drug Treatment Is Increasing
10.4.3 The R&D Pipeline is Well Stocked, But What Does This Mean for the Industry?

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 The Coagulation Factors: Compound Name, Associated Bleeding Disorder and Bleeding Severity
Table 2.2 Treatment for VWD: Drug, Mechanism of Action and Disease Type
Table 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Revenues ($m) and Market Shares (%), 2012
Table 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024
Table 3.3 The World Market by Bleeding Disorder: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 3.4 The World Market for Bleeding Disorders by Disorder: Grouped Revenue ($m) and Market Share (%) Forecasts, 2013-2024
Table 3.5 Haemophilia A: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.6 Haemophilia B: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.7 Thrombocytopenia: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 3.8 Other Coagulation Factor Deficiencies: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.1 The Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Revenues ($m) and Market Shares (%), 2012
Table 4.2 The Leading Drugs for the Bleeding Disorders: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 4.3 Leading Drugs: Grouped Revenue Forecasts ($m), 2013-2024
Table 4.4 Advate: Key Facts
Table 4.5 Advate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.6 NovoSeven: Key Facts
Table 4.7 NovoSeven: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.8 Kogenate: Key Facts
Table 4.9 Kogenate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.10 BeneFIX: Key Facts
Table 4.11 BeneFIX: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.12 FEIBA: Key Facts
Table 4.13 FEIBA: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.14 ReFacto/ Xyntha: Key Facts
Table 4.15 ReFacto/ Xyntha: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.16 Helixate: Key Facts
Table 4.17 Helixate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.18 Nplate: Key Facts
Table 4.19 Nplate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.20 Alphanate: Key Facts
Table 4.21 Alphanate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.22 Promacta: Key Facts
Table 4.23 Promacta: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.24 Rixubis: Key Facts
Table 4.25 Rixubis: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.26 Eloctate: Key Facts
Table 4.27 Eloctate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.28 Alprolix: Key Facts
Table 4.29 Alprolix: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.30 N8-GP: Key Facts
Table 4.31 N8-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 4.32 N9-GP: Key Facts
Table 4.33 N9-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.1 Leading National Markets for Bleeding Disorders: Revenues ($m) and Market Shares (%), 2012
Table 5.2 The Leading National Markets: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
Table 5.3 The Leading National Markets for Bleeding Disorders: Grouped Revenue Forecasts ($m), 2013-2024
Table 5.4 The US Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.5 The EU5 Bleeding Disorders Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2024
Table 5.6 The German Bleeding Disorder Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.7 The French Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.8 The Italian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.9 The UK Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.10 The Spanish Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.11 The Japanese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.12 The Chinese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.13 The Brazilian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.14 The Indian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 5.15 The Russian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
Table 6.1 Bleeding Disorders: Candidates in Pre-Registration, 2013
Table 6.2 Bleeding Disorders: Candidates in Phase III Development, 2013
Table 6.3 Bleeding Disorders: Candidates in Phase II/III Development, 2013
Table 6.4 Bleeding Disorders: Candidates in Phase I/II Development, 2013
Table 6.5 Bleeding Disorders: Candidates in Phase I Development, 2013
Table 7.1 The Leading Companies of the Bleeding Disorders Market: Revenues ($m) and Market Shares (%), 2012
Table 7.2 Baxter: Product Portfolio for Bleeding Disorders, 2013
Table 7.3 Novo Nordisk: Bleeding Disorders Product Portfolio, 2013
Table 7.4 Bayer: Bleeding Disorders Product Portfolio, 2013
Table 7.5 Pfizer: Bleeding Disorders Product Portfolio, 2013
Table 7.6 CSL Behring: Bleeding Disorders Product Portfolio, 2013
Table 7.7 Grifols: Bleeding Disorders Product Portfolio, 2013
Table 7.8 Amgen: Bleeding Disorders Product Portfolio, 2013
Table 7.9 Octapharma: Bleeding Disorders Product Portfolio, 2013
Table 7.10 GlaxoSmithKline: Bleeding Disorders Product Portfolio, 2013
Table 7.11 Biogen Idec: Bleeding Disorders Product Portfolio, 2013
Table 8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013
Table 8.2 Opportunities and Threats Facing the Bleeding Disorders Pharmaceutical Market, 2013-2024
Table 8.3 Social, Technological, Economic and Political Factors Influencing the Bleeding Disorders Market (STEP Analysis), 2013-2024

List of Figures

Figure 2.1 Diagram of the Coagulation Cascade
Figure 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Market Shares (%), 2012
Figure 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024
Figure 3.3 The World Market by Bleeding Disorder: Market Shares (%), 2018
Figure 3.4 The World Market by Bleeding Disorder: Market Shares (%), 2024
Figure 3.5 Haemophilia A: Revenue Forecast ($m), 2013-2024
Figure 3.6 The Haemophilia A Submarket: Driving and Restraining Factors, 2013
Figure 3.7 Haemophilia B: Revenue Forecast ($m), 2013-2024
Figure 3.8 The Haemophilia B Submarket: Driving and Restraining Factors, 2013
Figure 3.9 Thrombocytopenia: Revenue Forecast ($m), 2013-2024
Figure 3.10 The Thrombocytopenia Submarket: Driving and Restraining Factors, 2013
Figure 3.11 Other Coagulation Factor Deficiencies: Revenue Forecast ($m), 2013-2024
Figure 4.1 Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Market Shares (%), 2012
Figure 4.2 Leading Drugs for Bleeding Disorders: Market Shares (%), 2018
Figure 4.3 Leading Drugs for Bleeding Disorders: Market Shares (%), 2024
Figure 4.4 Advate: Revenue Forecast ($m), 2013-2024
Figure 4.5 NovoSeven: Revenue Forecast ($m), 2013-2024
Figure 4.6 Kogenate: Revenue Forecast ($m), 2013-2024
Figure 4.7 BeneFIX: Revenue Forecast ($m), 2013-2024
Figure 4.8 FEIBA: Revenue Forecast ($m), 2013-2024
Figure 4.9 ReFacto/ Xyntha: Revenue Forecast ($m), 2013-2024
Figure 4.10 Helixate: Revenue Forecast ($m), 2013-2024
Figure 4.11 Nplate: Revenue Forecast ($m), 2013-2024
Figure 4.12 Alphanate: Revenue Forecast ($m), 2013-2024
Figure 4.13 Promacta: Revenue Forecast ($m), 2013-2024
Figure 4.14 Rixubis: Revenue Forecast ($m), 2013-2024
Figure 4.15 Eloctate: Revenue Forecast ($m), 2013-2024
Figure 4.16 Alprolix: Revenue Forecast ($m), 2013-2024
Figure 4.17 N8-GP: Revenue Forecast ($m), 2013-2024
Figure 4.18 N9-GP: Revenue Forecast ($m), 2013-2024
Figure 5.1 Leading National Markets for Bleeding Disorders: Market Share (%), 2012
Figure 5.2 Leading National Markets for Bleeding Disorders: Market Shares (%), 2018
Figure 5.3 Leading National Markets for Bleeding Disorders: Market Share (%), 2024
Figure 5.4 The US Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.5 The EU5 Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.6 The German Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.7 The French Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.8 The Italian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.9 The UK Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.10 The Spanish Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.11 The Japanese Bleeding Disorders Market: Revenue Forecast ($m) 2013-2024
Figure 5.12 The Chinese Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.13 The Brazilian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.14 The Indian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 5.15 The Russian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
Figure 6.1 Overview of R&D Pipeline for Bleeding Disorders: Candidates Filed for Approval or in Phase III Trials, 2013
Figure 7.1 Leading Companies of the Bleeding Disorders Market: Market Share (%), 2012
Figure 10.1 The World Market for Bleeding Disorders by Disorder: Comparison of Revenues ($m), 2012-2024
Figure 10.2 Leading Drugs of the Bleeding Disorders Market: Comparison of Revenues ($m), 2012, 2018 and 2024
Figure 10.3 Leading National Markets for Bleeding Disorders: Comparison of Revenues ($m), 2012, 2018 and 2024

Companies Listed

Amgen
AryoGen Biopharma
Asklepios Biopharmaceuticals
Baxter
Bayer
Beijing Northland Biotech
Biogen Idec
Brazilian Ministry of Health
Canadian Haemophilia Society
Cangene Corporation
Catalyst Biosciences
Chatham Therapeutics
CSL Behring
Eisai
Empresa Brasileira de Hemoderivadose Biotechnologia
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Genetics Institute
GlaxoSmithKline (GSK)
Green Cross Corporation
Grifols Biologicals
Haemophilia Centres of England, Scotland, Northern Ireland or Wales
Haemophilia Treatment Centre Collaborative Network of China (HTCCNC)
Haemophilialife
Hemobrás
Inspiration Biopharmaceuticals
Ipsen Pharma
Italian Association of Haemophilia Centres (AICE)
Johns Hopkins Medicine
Ligand Pharmaceuticals
National Health Service (NHS)
National Heart, Lung and Blood Institute
Nektar Therapeutics
Novo Nordisk
Octapharma
Pfizer
Shenyang Sunshine Pharmaceutical Co.
Spanish Haemophilia Society
Swedish Orphan Biovitrum
United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO)
US Food and Drug Administration (FDA)
World Federation of Haemophilia


Read the full report:
Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

http://www.reportbuyer.com/pharma_healthcare/diseases/bleeding_disorders_world_pharmaceutical_industry_market_2014_2024.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


Source: PR Newswire



comments powered by Disqus